{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T09:40:55Z","timestamp":1786441255357,"version":"build-2736575974"},"reference-count":42,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Cardio"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n A 12-week digital health program for nonalcoholic fatty liver disease (NAFLD) previously showed feasibility in engagement, program retention, and clinical outcomes. This study investigates whether improvements in cardiometabolic risk factors achieved during a 12-week active program were sustained over a subsequent 6-month follow-up period.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n The primary objective of this analysis was to evaluate whether the clinical improvements achieved after a 12-week program were maintained over the subsequent 6-month period, which did not include coaching or new intervention materials. In addition, the study aimed to assess participants\u2019 retention and engagement with the maintenance program.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n In a 9-month, single-arm study using the Sidekick app (Sidekick Health), individuals with NAFLD and BMI >30 or metabolic syndrome or type 2 diabetes were included. The initial 12 weeks focused on providing education about diet, physical activity, stress management, and sleep, followed by 6 months without coaching or new intervention materials. The measured outcomes encompassed demographics, body composition, liver fat assessed using magnetic resonance imaging-proton density fat fraction (MRI-PDFF), and blood markers.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of the 34 participants who completed the first 12 weeks, 28 (82%) completed the 9-month study measurements. The median age was 63.0 years (IQR 53.5\u201071.0) and 57.1% (16\/28) were women. At 9 months, compared to baseline, the mean weight loss was 4.0 kg (SD 5.0;\n P<\/jats:italic>\n <.001). Liver fat decreased by 2.5% (SD 4.5;\n P<\/jats:italic>\n <.001), with an 18.4% relative reduction. Systolic blood pressure decreased by 8.3 mm Hg (SD 13.4,\n P<\/jats:italic>\n <.001) and diastolic by 2.5 mm Hg (SD 6.0;\n P<\/jats:italic>\n =.02). Waist circumference decreased by 4.7 cm (SD 7.1;\n P<\/jats:italic>\n <.001) and median glycated hemoglobin A1c (HbA\n 1c<\/jats:sub>\n ) decreased by 19.5 mmol\/mol (\n P<\/jats:italic>\n <.001).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Sustained improvements in liver fat and metabolic markers suggest that Sidekick Health\u2019s digital program is a promising strategy for managing NAFLD without requiring continuous coaching.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/72074","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T20:45:07Z","timestamp":1754426707000},"page":"e72074-e72074","source":"Crossref","is-referenced-by-count":2,"title":["Long-Term Feasibility and Outcomes of a Digital Health Program to Improve Liver Fat and Cardiometabolic Markers in Individuals With Nonalcoholic Fatty Liver Disease: Prospective Single-Arm Feasibility Study"],"prefix":"10.2196","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3320-5972","authenticated-orcid":false,"given":"Sigridur","family":"Bj\u00f6rnsdottir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0301-7710","authenticated-orcid":false,"given":"Hildigunnur","family":"Ulfsdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7661-4872","authenticated-orcid":false,"given":"Elias Freyr","family":"Gudmundsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8851-3692","authenticated-orcid":false,"given":"Bartosz","family":"Dobies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3148-5210","authenticated-orcid":false,"given":"Kolbrun","family":"Sveinsdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7957-6285","authenticated-orcid":false,"given":"Ari Pall","family":"Isberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8441-0017","authenticated-orcid":false,"given":"Gudlaug E A","family":"Magnusdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2419-8846","authenticated-orcid":false,"given":"Thrudur","family":"Gunnarsdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5505-3607","authenticated-orcid":false,"given":"Tekla","family":"Karlsdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1377-768X","authenticated-orcid":false,"given":"Gudlaug","family":"Bjornsdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5439-3389","authenticated-orcid":false,"given":"Sigurdur","family":"Sigurdsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9427-443X","authenticated-orcid":false,"given":"Saemundur","family":"Oddsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5696-0084","authenticated-orcid":false,"given":"Vilmundur","family":"Gudnason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"issue":"12","key":"R1","doi-asserted-by":"publisher","DOI":"10.3390\/nu11122878","article-title":"Dietary patterns and components in Nonalcoholic Fatty Liver Disease (NAFLD): what key messages can health care providers offer?","volume":"11","author":"Riazi","journal-title":"Nutrients"},{"issue":"1","key":"R2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3325\/cmj.2021.62.1","article-title":"Nonalcoholic fatty liver disease - a growing public health problem","volume":"62","author":"Mikola\u0161evi\u0107","journal-title":"Croat Med J"},{"issue":"3","key":"R3","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","article-title":"Changing epidemiology, global trends and implications for outcomes of NAFLD","volume":"79","author":"Wong","journal-title":"J Hepatol"},{"issue":"6","key":"R4","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases","volume":"66","author":"Adams","journal-title":"Gut"},{"issue":"3","key":"R5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17030367","article-title":"Bidirectional relationships and disconnects between NAFLD and features of the metabolic syndrome","volume":"17","author":"Wainwright","journal-title":"Int J Mol Sci"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1177\/20420188221145549","article-title":"MAFLD: a multisystem disease","volume":"14","author":"Pipitone","journal-title":"Therapeutic Advances in Endocrinology"},{"issue":"Suppl","key":"R7","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.3350\/cmh.2022.0351","article-title":"Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease","volume":"29","author":"Konyn","journal-title":"Clin Mol Hepatol"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.21037\/tgh-2020-15","article-title":"Liver transplantation in patients with non-alcoholic steatohepatitis and alcohol-related liver disease: the dust is yet to settle","volume":"7","author":"Satapathy","journal-title":"Transl Gastroenterol Hepatol"},{"issue":"8","key":"R9","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.4254\/wjh.v15.i8.1001","article-title":"Emerging therapeutic options for non-alcoholic fatty liver disease: A systematic review","volume":"15","author":"Tidwell","journal-title":"World J Hepatol"},{"issue":"7","key":"R10","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.sjbs.2018.12.016","article-title":"Lifestyle interventions for non-alcoholic fatty liver disease","volume":"26","author":"Ahmed","journal-title":"Saudi J Biol Sci"},{"issue":"4","key":"R11","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000575","article-title":"Digital therapeutics: emerging new therapy for nonalcoholic fatty liver disease","volume":"14","author":"Zhou","journal-title":"Clin Transl Gastroenterol"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.2196\/52576","article-title":"User engagement, acceptability, and clinical markers in a digital health program for nonalcoholic fatty liver disease: prospective, single-arm feasibility study","volume":"8","author":"Bj\u00f6rnsdottir","journal-title":"JMIR Cardio"},{"issue":"6","key":"R13","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","journal-title":"J Hepatol"},{"issue":"4","key":"R14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.20517\/mtod.2024.54","article-title":"NAFLD to MAFLD: collaboration, not confusion - rethinking the naming of fatty liver disease","volume":"4","author":"Sanal","journal-title":"Metab Target Organ Damage"},{"issue":"2","key":"R15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.20517\/mtod.2024.06","article-title":"MASLD, MAFLD, or NAFLD criteria: have we re-created the confusion and acrimony surrounding metabolic syndrome?","volume":"4","author":"Byrne","journal-title":"Metab Target Organ Damage"},{"issue":"5","key":"R16","doi-asserted-by":"publisher","first-page":"e192","DOI":"10.1016\/j.jhep.2024.01.012","article-title":"Researchers call for more flexible editorial conduct rather than abruptly adopting only the new MASLD nomenclature","volume":"80","author":"Lonardo","journal-title":"J Hepatol"},{"issue":"2","key":"R17","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3350\/cmh.2019.0001n","article-title":"Application of transient elastography in nonalcoholic fatty liver disease","volume":"26","author":"Zhang","journal-title":"Clin Mol Hepatol"},{"issue":"5","key":"R18","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1007\/s00261-017-1048-0","article-title":"Accurate simultaneous quantification of liver steatosis and iron overload in diffuse liver diseases with MRI","volume":"42","author":"Fran\u00e7a","journal-title":"Abdom Radiol (NY)"},{"issue":"1","key":"R19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jocd.2008.09.004","article-title":"iDXA, Prodigy, and DPXL dual-energy x-ray absorptiometry whole-body scans: a cross-calibration study","volume":"12","author":"Hull","journal-title":"J Clin Densitom"},{"issue":"2","key":"R20","doi-asserted-by":"publisher","DOI":"10.3390\/life11020143","article-title":"FIB-4 first in the diagnostic algorithm of metabolic-dysfunction-associated fatty liver disease in the era of the global metabodemic","volume":"11","author":"Sumida","journal-title":"Life (Basel)"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100780","article-title":"Prognostic utility of Fibrosis-4 Index for risk of subsequent liver and cardiovascular events, and all-cause mortality in individuals with obesity and\/or type 2 diabetes: a longitudinal cohort study","volume":"36","author":"Anstee","journal-title":"Lancet Reg Health Eur"},{"issue":"2","key":"R22","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1348\/014466505X29657","article-title":"The short\u2010form version of the Depression Anxiety Stress Scales (DASS\u201021): Construct validity and normative data in a large non\u2010clinical sample","volume":"44","author":"Henry","journal-title":"British J Clinic Psychol"},{"issue":"5","key":"R23","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/j.1751-7176.2008.07572.x","article-title":"Predictive validity of a medication adherence measure in an outpatient setting","volume":"10","author":"Morisky","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"8","key":"R24","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1056\/NEJMoa1611179","article-title":"Effect of intensive blood-pressure treatment on patient-reported outcomes","volume":"377","author":"Berlowitz","journal-title":"N Engl J Med"},{"issue":"8","key":"R25","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJMsa1616035","article-title":"Cost-effectiveness of intensive versus standard blood-pressure control","volume":"377","author":"Bress","journal-title":"N Engl J Med"},{"issue":"10","key":"R26","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1111\/jgh.15589","article-title":"Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease","volume":"36","author":"Tamaki","journal-title":"J of Gastro and Hepatol"},{"issue":"1","key":"R27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.carpath.2006.04.006","article-title":"C-reactive protein: a nontraditional serum marker of cardiovascular risk","volume":"16","author":"de Ferranti","journal-title":"Cardiovasc Pathol"},{"issue":"30","key":"R28","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011639","article-title":"Waist-hip ratio as a predictor of myocardial infarction risk: A systematic review and meta-analysis","volume":"97","author":"Cao","journal-title":"Medicine (Baltimore)"},{"issue":"20","key":"R29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20205037","article-title":"Development and progression of non-alcoholic fatty liver disease: the role of advanced glycation end products","volume":"20","author":"Fernando","journal-title":"Int J Mol Sci"},{"issue":"1","key":"R30","doi-asserted-by":"publisher","first-page":"76","DOI":"10.14218\/JCTH.2019.00051","article-title":"Non-alcoholic fatty liver disease: growing burden, adverse outcomes and associations","volume":"8","author":"Kumar","journal-title":"J Clin Transl Hepatol"},{"issue":"2","key":"R31","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","journal-title":"Gastroenterology"},{"issue":"11","key":"R32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0111808","article-title":"Weight loss in nonalcoholic fatty liver disease patients in an ambulatory care setting is largely unsuccessful but correlates with frequency of clinic visits","volume":"9","author":"Dudekula","journal-title":"PLoS ONE"},{"issue":"12","key":"R33","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1016\/j.cgh.2017.06.011","article-title":"Lifestyle behavior change in patients with nonalcoholic fatty liver disease: a qualitative study of clinical practice","volume":"15","author":"Avery","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1177\/20552076231187597","article-title":"The effects of electronic-based lifestyle interventions on nonalcoholic fatty liver disease: A systematic review","volume":"9","author":"Seifi","journal-title":"Digit HEALTH"},{"issue":"2","key":"R35","doi-asserted-by":"publisher","first-page":"135","DOI":"10.4103\/tcmj.tcmj_86_20","article-title":"Role of diet and lifestyle modification in the management of nonalcoholic fatty liver disease and type 2 diabetes","volume":"33","author":"Prabhakar","journal-title":"Tzu Chi Med J"},{"issue":"3","key":"R36","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2174\/1570161115666170621080835","article-title":"Lifestyle modifications in non-alcoholic fatty liver disease and non- alcoholic steatohepatitis","volume":"16","author":"Stavropoulos","journal-title":"CVP"},{"key":"R37","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","journal-title":"Mol Metab"},{"issue":"2","key":"R38","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11020073","article-title":"Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials","volume":"11","author":"Mantovani","journal-title":"Metabolites"},{"issue":"2","key":"R39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24021703","article-title":"GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives","volume":"24","author":"Nevola","journal-title":"Int J Mol Sci"},{"issue":"5","key":"R40","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.arcmed.2011.08.004","article-title":"Treatment of atherogenic liver based on the pathogenesis of nonalcoholic fatty liver disease: a novel approach to reduce cardiovascular risk?","volume":"42","author":"Maurantonio","journal-title":"Arch Med Res"},{"issue":"6","key":"R41","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.jhep.2024.06.030","article-title":"Differing genetic variants associated with liver fat and their contrasting relationships with cardiovascular diseases and cancer","volume":"81","author":"Ahmed","journal-title":"J Hepatol"},{"issue":"4","key":"R42","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/hep.30626","article-title":"Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps","volume":"70","author":"Lonardo","journal-title":"Hepatology"}],"container-title":["JMIR Cardio"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cardio.jmir.org\/2025\/1\/e72074","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:02:10Z","timestamp":1782842530000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardio.jmir.org\/2025\/1\/e72074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":42,"URL":"https:\/\/doi.org\/10.2196\/72074","relation":{},"ISSN":["2561-1011"],"issn-type":[{"value":"2561-1011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,12]]},"article-number":"v9i12e72074"}}